07:00 , May 2, 2011 |  BC Week In Review  |  Clinical News

Bone Marrow Aspiration Concentrate: Phase I started

Harvest began the open-label, international Phase I REVIVE-1 trial to evaluate a coronary sinus infusion of 60 mL BMAC in about 60 patients. Harvest Technologies Corp., Plymouth, Mass.   Product: Bone Marrow Aspiration Concentrate (BMAC)...
07:00 , Mar 28, 2011 |  BC Week In Review  |  Clinical News

Bone Marrow Aspiration Concentrate: Pivotal trial start

Next quarter, Harvest will begin a double-blind, placebo-controlled, U.S. pivotal trial in 210 patients to evaluate 40 mL BMAC injected into ischemic tissues of the lower limb. Harvest Technologies Corp., Plymouth, Mass.   Product: Bone...
08:00 , Dec 7, 2009 |  BC Week In Review  |  Clinical News

BMAC: Phase I/II data

An open-label, Indian Phase I/II trial in 60 patients showed that 90% of patients avoided leg amputation at 12 weeks after receiving BMAC. BMAC also led to a significant reduction in pain perception, and significant...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Clinical News

BMAC: Completed feasibility study enrollment

Harvest completed enrollment of 48 patients in a U.S. and Indian feasibility study evaluating its BMAC system. Harvest Technologies Corp., Plymouth, Mass.   Product: BMAC, bone marrow nucleated cells   Business: Cardiovascular   Molecular target: NA   Description:...
07:00 , Apr 13, 2009 |  BC Week In Review  |  Clinical News

BMAC: Interim Phase I/II data

Interim data from the first 30 patients in an open-label, Indian Phase I/II trial showed that 88% of patients avoided leg amputation at 12 weeks after receiving nucleated BMAC. Patients also reported significantly improved quality...